Aldevron News: Partnerships

Aldevron Acquires Nature Technology Corporation

Acquisition combines Aldevron's leadership in GMP manufacturing with Nature Tech's portfolio of proprietary technologies.

Aldevron has acquired Nature Technology Corporation (NTC), a developer of innovative and proprietary plasmid constructs and manufacturing solutions that are used in the field of cell and gene therapy. NTC's nucleic acid-based technologies include NanoplasmidTM, a proprietary vector construct that improves the safety and performance of plasmids and biologics. Aldevron and NTC have complementary service offerings and pairing Aldevron's world-class manufacturing capabilities with NTC's innovative solutions will further support our clients and the patients they serve.

For more information about Nature Technology Corporation's full suite of offerings, visit www.natx.com

To get started now, complete the form, and a client relations representative will be in contact very soon.

Read More

In the News: Isolere Bio Enters into Agreement with Aldevron to Develop a Scalable Manufacturing Process for IsoTag Reagents

Isolere  Bio, a biotech firm working to develop a low-cost, high throughput, and scalable purification platform, has entered into an agreement with Aldevron , a leading research to GMP biomanufacturer of plasmid DNA, mRNA, and proteins, to develop a low-cost manufacturing strategy for its IsoTag™ reagents, that is able to easily scale up to meet demand for an industry that is seeing tremendous growth and bottleneck pressures.
Read More

In the News: AavantiBio and Aldevron Announce Strategic Partnership to Develop Next Generation Gene Therapies for Rare Genetic Diseases

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins and mRNA for the biotech industry, today announced a long-term strategic partnership for the supply of plasmid DNA that will enable AavantiBio to advance its platform of innovative gene transfer therapies.
Read More

In the News: Aruvant Partners with Aldevron to Provide Key Plasmid Raw Materials Used to Manufacture Pipeline Products

Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Aldevron, the leading provider of high-quality plasmid DNA, mRNA and recombinant proteins necessary for vaccines, gene and cell therapy, gene editing and diagnostic applications, announced today that Aldevron will support the development of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD), and ARU-2801, a one-time investigational gene therapy for hypophosphatasia (HPP). Aldevron will provide good manufacturing practice (GMP)-grade plasmid for Aruvant’s upcoming ARU-1801 pivotal trial.

Read More

In the News: Moderna and Aldevron Announce Expanded Partnership for mRNA Vaccine and Therapeutic Pipeline

Moderna, Inc. (Nasdaq:MRNA), and Aldevron have announced their expanded collaboration in support of the Moderna COVID-19 Vaccine and additional programs in Moderna’s clinical development pipeline. Specifically, Aldevron will supply plasmid DNA to serve as the genetic template for generating the COVID-19 mRNA vaccine and other investigational programs in Moderna’s pipeline.

Read More